Safety

Fazaclo (clozapine) orally disintegrating tablet

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) –

September 2015

Summary View

BOXED WARNING - updated/truncated to show changes

WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPE; SEIZURE; MYOCARDITIS AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Severe Neutropenia
  • Clozapine treatment has caused severe neutropenia, defined as an absolute neutrophil count (ANC) less than 500/µL. Severe neutropenia can lead to serious infection and death. Prior to initiating treatment with Fazaclo a baseline ANC must be at least 1500/µL for the general population; and must be at least 1000/µL for patients with documented Benign Ethnic Neutropenia (BEN). During treatment, patients must have regular ANC monitoring. Advise patients to immediately report symptoms consistent with severe neutropenia or infection (e.g., fever, weakness, lethargy, or sore throat). Because of the risk of severe neutropenia, Fazaclo is available only through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program…

CONTRAINDICATIONS

Hypersensitivity
  • Fazaclo is contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of Fazaclo

WARNINGS AND PRECAUTIONS

Severe Neutropenia
  • * update the neutropenia monitoring algorithms and associated Fazaclo (clozapine) treatment recommendations; and to accommodate for Fazaclo (clozapine) treatment for patients with benign ethnic neutropenia
Clozapine REMS Program
  • *updated

SPECIAL POPULATIONS

Hospice Patients
  • For hospice patients (i.e., terminally ill patients with an estimated life expectancy of six months or less), the prescriber may reduce the ANC monitoring frequency to once every 6 months, after a discussion with the patient and his/her caregiver. Individual treatment decisions should weigh the importance of monitoring ANC in the context of the need to control psychiatric symptoms and the patient’s terminal illness.

 

January 2012

Summary View

WARNINGS

QT Interval Prolongation
  • QT prolongation is associated with an increased risk for life-threatening ventricular arrhythmias including Torsades de Pointes. Treatment with FazaClo (clozapine, USP) has been associated with QT prolongation as well as ventricular arrthymia, Torsades de Pointes, cardiac arrest, and sudden death. Caution should be exercised when .....

PRECAUTIONS

Drug Interactions and Pharmacodynamic-Related Interactions:
QT prolongation: 
  • Treatment with FazaClo® (clozapine, USP) , has been associated with QT interval prolongation and fatal arrhythmia......
Pharmacokinetic-related Interactions
QT Prolongation: 
  • Use caution when prescribing FazaClo......

ADVERSE REACTIONS

Postmarketing Clinical Experience:
Cardiovascular System
  • Ventricular tachycardia, cardiac arrest, QT prolongation, and Torsades de Pointes.

 

September 2010

Summary View 

PRECAUTIONS

Cerebrovascular adverse events
  • An increased risk of cerebrovascular adverse events has been seen in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. Clozaril should be used with caution in patients with risk factors for stroke.

ADVERSE REACTIONS

Postmarketing Clinical Experience
  • Central Nervous System: obsessive compulsive symptoms
  • Metabolic and Nutritional Disorders: new onset diabetes
  • Respiratory System: pneumonia and lower respiratory tract infection which may be fatal

 

Page Last Updated: 10/09/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.